Generation of Knockout Rats with X-Linked Severe Combined Immunodeficiency (X-SCID) Using Zinc-Finger Nucleases by Mashimo, Tomoji et al.
Generation of Knockout Rats with X-Linked Severe
Combined Immunodeficiency (X-SCID) Using Zinc-Finger
Nucleases
Tomoji Mashimo
1*, Akiko Takizawa
1, Birger Voigt
1, Kazuto Yoshimi
1, Hiroshi Hiai
2, Takashi Kuramoto
1,
Tadao Serikawa
1
1Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Shiga Medical Center for Adult Disease, Moriyama, Japan
Abstract
Background: Although the rat is extensively used as a laboratory model, the inability to utilize germ line-competent rat
embryonic stem (ES) cells has been a major drawback for studies that aim to elucidate gene functions. Recently, zinc-finger
nucleases (ZFNs) were successfully used to create genome-specific double-stranded breaks and thereby induce targeted
gene mutations in a wide variety of organisms including plants, drosophila, zebrafish, etc.
Methodology/Principal Findings: We report here on ZFN-induced gene targeting of the rat interleukin 2 receptor gamma (Il2rg)
locus, where orthologous human and mouse mutations cause X-linked severe combined immune deficiency (X-SCID). Co-injection
of mRNAs encoding custom-designed ZFNs into the pronucleus of fertilized oocytes yielded genetically modified offspring at rates
greater than 20%, which possessed a wide variety of deletion/insertion mutations. ZFN-modified founders faithfully transmitted
their genetic changes to the next generation along with the severe combined immune deficiency phenotype.
Conclusions and Significance: The efficient and rapid generation of gene knockout rats shows that using ZFN technology is
a new strategy for creating gene-targeted rat models of human diseases. In addition, the X-SCID rats that were established
in this study will be valuable in vivo tools for evaluating drug treatment or gene therapy as well as model systems for
examining the treatment of xenotransplanted malignancies.
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Introduction
Although several strategies are available for producing a wide
variety of genomic alterations in the mouse, the same cannot be said
of the rat. Rat ES cells [1,2] and induced pluripotent stem cells (iPS)
[3,4] are available, but the culture conditions for these cells and the
methodology for inducing homologous recombination are imperfect
[5]. Rat spermatogonial stem cells (SSC) have also been isolated and
cultivated in vitro but their yield proved unsatisfactory in terms of their
ability to undergo homologous recombination [6,7]. Besides these
methods which are based on the in vitro genetic engineering of
pluripotent stem cells, transposon-mediated mutagenesis [8] and N-
ethyl-N-nitrosourea (ENU) mutagenesis [9,10] have been used with
some success for producing mutations in the rat genome. We recently
reported on a high-throughput gene-driven strategy which uses the
mutagen ENU and the Mu-transposition reaction (MuT-POWER)
to rapidly detect induced mutations. This was in addition to our
investigation of intracytoplasmic sperminjection (ICSI) for recovering
heterozygous genotypes of interest out of a large sperm cell repository
[11,12]. However, even if a large number of mutant strains already
exists or may potentially be available, targeted modification or
disruption of specific DNA regions is difficult to achieve. Even in the
case of our gene-driven strategy,X-linked mutations are impossible to
obtain because of the breeding protocol which is used [11].
Recently, a novel gene-targeting technology which employs
zinc-finger nucleases (ZFNs) has been proven to work successfully
in plants, Caenorhabditis elegans, frogs, drosophila, zebrafish, and
human ESCs and iPSCs [13,14,15]. ZFNs are chimeric proteins
that consist of a specific DNA-binding domain which is made of
tandem zinc finger-binding motifs that are fused to a non-specific
cleavage domain of the restriction endonuclease FokI. ZFNs can
create site-specific double-stranded breaks which are repaired via
non-homologous end joining (NHEJ), a process that results in the
arbitrary addition or deletion of base pairs. Consequently, repair
by NHEJ is mutagenic and results in a knockout. Recently, it was
reported that a single injection of DNA or messenger RNA that
encodes specific ZFNs into one-cell transgenic rat embryos that
express GFP could lead to a high frequency of animals that do not
express the transgenic marker as a consequence of homologous
recombination at the GFP site [16]. Here, we report on an
experiment that involved using ZFN technology. The aim of the
experiment was to inactivate the gene that encodes the interleukin
2 receptor gamma (Il2rg), which is essential for signaling by
interleukins such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In
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combined immunodeficiency (X-SCID), one of the most common
forms of human SCID [17,18]. A major motivation for performing
this experiment was the observation that although SCID mouse
animal models are the most commonly used in research on drug
development, an X-SCID immunodeficient rat model would
complement mouse models through the additional advantage of
being employed for testing the pharmacodynamics and toxicity of
potential therapeutic compounds. Following the results of research
involving Prkdc SCID [19,20] and Il2rg X-SCID mice [21,22,23],
Il2rg X-SCID rats should have a very low level of NK cell activity
and thereby make xenotransplantation more successful.
Results
Injection of Il2rg ZFN-encoding mRNA into rat embryos
Of 443 ZFN-injected embryos, 230 (51.9%) were transferred
into the oviducts of pseudopregnant female rats, and 54 (24.3%) of
these embryos were successfully carried to term as shown in
Figure 1a, b and Table 1. Sequence analysis of the ZFN target site
of these 54 founder animals revealed that 5 males and 8 females
(24.1%) carried a variety of mutations including from 3 to1,097 bp
deletions and a 1 bp insertion in the region which overlapped the
ZFN target site as seen in Figure 1c and Figure S1. Four out of five
of the males carried different biallelic mutations at the Il2rg locus
despite them only having one X chromosome. This suggests that
mosaicism was induced by the ZFN treatment, a situation which is
frequently observed in the DNA of transgenic founders. Three of
the affected females had a monoallelic homozygous mutation, four
had heterologous or mosaicism biallelic mutations, and the
remainder had three different mosaic mutations. The normal
F344-allele was not found in the affected founder animals. Most of
these mutations were expressed as frameshifts or splicing errors
and resulted in no or very little IL2RG mRNA being expressed as
shown in Figure 1d probably due to nonsense-mediated decay.
Western blotting with antibodies against the C-terminal domain of
Figure 1 Injection of Il2rg ZFN-encoding mRNA into rat embryos induced targeted loss-of-function mutations. (a) Schematic
representation of the rat Il2rg gene. Exons are represented as blue boxes. Regions used to design the ZFN templates are printed in red for the left ZFN
and green for the right ZFN. The magnified views illustrate the binding sites for the ZFN pairs. Please see Figure S4 for further details. (b) Schematic
representation of the method used for ZFN-targeted mutagenesis in rat embryos. (c) Sequencing assay for ZFN-induced mutations in the Il2rg-
targeted region. Multiple deletions or insertions depicted using red dashes or letters, respectively, are aligned along the wild-type sequences shown
on the top line. (d) RT-PCR analysis of IL2RG mRNA expression in the spleen of control F344, founder (G0), and G1 rats. GAPDH expression was used as
an internal control. (e) Western blotting for IL2RG protein in the spleen of control F344, founder (G0), and G1 rats. b-actin was used as a loading
control. (f) ELISA for serum IgG, IgA, and IgM levels in control F344, founder (G0), and G1 rats. *P,0.01, **P,0.001, and ***P,0.0001, indicated for
each group in comparison with control F344 for independent sample Student t-tests.
doi:10.1371/journal.pone.0008870.g001
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in Figure 1e.
To clarify whether the ZFNs only induced mutations in the
targeted region, we checked 16 sites that showed a high rate of
similarity with the targeted site at the sequence level with no more
than 6 to 7 bp mismatches as illustrated in Table S1. Insertions or
deletions were not observed at any of these off-target sites among
the 13 ZFN-modified founders. This confirms that ZFNs can be
reliably and efficiently used to produce mutant alleles at loci of
interest. Although we cannot exclude the possibility that the ZFNs
may have cleaved unknown off-target sites, such undesired
mutations can subsequently be easily excluded from the genome
of the carrier animals by backcrossing to the parental strain or
another background strain.
Germ line transmission of ZFN-modified genetic changes
To assess the transmission of ZFN-modified genetic changes to
the next generation, we crossed the founder animals with the
background strain F344/Stm as depicted in Table S2. All 38
offspring consisting of 18 males and 20 females that were obtained
from the founder females mated with the F344 males had one of
the maternal mutations. This indicates that ZFN-induced
mutations were faithfully transmitted through the germ line. In
the offspring that were obtained from the founder males, there
were two cases where only one of the paternal bialleles was
transmitted or both alleles were transmitted. This suggests that
mosaicism occurred not only in somatic cells but also in the germ
line of the founder animals. PCR analysis of genomic DNA
isolated from several types of tissues indicated that somatic
mosaicism occurred in the progenitors but not in their offspring as
shown in Figure S2.
We intercrossed the G0 founders to produce hemizygous males
(Il2rg
2/Y) and homozygous females (Il2rg
2/Il2rg
2) for the ZFN-
induced mutation listed in Table S3 to characterize the
immunodeficient phenotypes of the X-SCID rats. The hemizygous
males and homozygous females appeared normal at birth and
developed well as shown in Figure 2a. RT-PCR and Western blot
assays was performed on these G1 rats and the results showed a
complete loss of expression of the Il2rg gene as detailed in
Figures 1d, e. ELISA for serum immunoglobulin (Ig) levels
revealed reduced IgG, diminished IgA, and increased IgM levels
in the G1 rats as noted in Figure 1f.
Characterization of Il2rg-deficient X-SCID rats
Gross and microscopic analyses at five weeks of age showed that
the X-SCID rats underwent abnormal lymphoid development as
depicted in Figure 2. The thymus of X-SCID rats was extremely
hypoplastic as seen in Figure 2b and consisted of an epithelial
rudiment without any lymphocytes as seen in Figure 2d. The
spleen was moderately decreased in size as noted in Figure 2c, and
the white pulp was severely hypoplastic and the red pulp contained
myeloid cells as shown in Figure 2f. Peripheral lymph nodes and
Peyer’s patches were not identified by necropscopy. In the
peripheral blood (PB) profiles, the numbers of white blood cells
(WBCs) was reduced compared to those of control rats as detailed
in Table S4. Differential counts of WBCs showed a dramatic
decrease in leukocytes in the X-SCID rats (Table S5). Flow
cytometry analysis of cell populations isolated from PB, bone
marrow (BM), and the spleen also revealed a dramatic decrease in
the number of the lymphocytes as seen in Figure 2h and Figure S3.
The number of CD4
2CD8
+ T-cells was markedly diminished and
the number of CD4
+CD8
2 T-cells was decreased although some
cells were present in PB, BM and the spleen. The numbers of
CD3
2CD45RA
+ B-cells and CD3
2CD161a
+ NK cells were
markedly diminished in PB and BM, but some cells were present
in the spleen. Heterozygous females exhibited normal lymphoid
development and were indistinguishable from normal control
females (data not shown).
Xenotransplantation of human tumor cells
These immunodeficient phenotypes of the X-SCID rats were
very similar to those of the previously reported X-SCID mice and
were characterized by a nearly complete lack of T-cells, B-cells
and NK cells [21,22,23]. Since X-SCID mice cannot reject
transplanted tissues from other species including humans, we
tested Il2rg-deficient rats as a host for xenotransplantation of
human ovarian cancer tumor cells. All X-SCID rats developed
tumors within 14 days after injection of the cells (6/6, 100%),
while control F344 rats showed no tumor growth (0/6, 0%) as seen
in Figure 3a, b. The tumors were confirmed by histological
analysis as depicted in Figure 3c and by PCR with primers that
were used to amplify the human MHC class II DQB2 region (data
not shown). These observations illustrate the impaired immune
system function of X-SCID rats and suggest that the animals may
be important models for cancer and transplantation research.
Discussion
In this study, we proved that targeted gene disruption using
ZFN technology works well and provides for several advantages
and possibilities when used in rats. First and foremost, knockout
rats can be created in a four- to six-month time frame and with
high efficiency at more than 20%. This is more favorable than the
ES cell-based method for mice that usually takes 12–18 months.
Given the high rate of germ line transmission, preliminary
phenotypic analysis can be performed on G1 animals after
intercrossing the initial G0 founders, thereby saving time and
effort. Second, gene-targeting with ZFNs does not seem to be
strain-dependent (unpublished data) and accordingly can be
performed with any inbred strain. This is of great advantage
Table 1. Injection of ZFN-encoding mRNA into fertilized oocytes.
Strain Oocyte state Injected oocytes Transferred oocytes (%) Born (%) Mutants (%)
F344/Stm Fresh 234 32 (-) =2,R5 (21.9) R2 (28.6)
Cryopreserved
a 57 (-) =8,R10 (31.6) R2 (11.1)
Fresh 182 129 (68.3) =16,R11 (20.9) =4,R4 (29.6)
TM/Kyo Fresh 27 12 (44.4) =1,R1 (16.7) =1 (50.0)
Total 443 230 (51.9) =27,R27 (24.3) =5,R8 (24.1)
aInjected oocytes were cultured in KRB overnight and cryopreserved at the two-cell stage.
doi:10.1371/journal.pone.0008870.t001
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efficiency when used with different strains. This provides a straight
forward strategy for directly employing targeted gene disruption in
the existing strain, thereby bypassing tedious and time-consuming
backcrossing steps that generally take two to three years to
complete. Third, ZFNs can be used to induce a wide variety of
allelic changes covering small or wide deletions or insertions. They
may be used to produce frameshifts or small in-frame deletions
such as the 3-bp deletion that we observed. Given the reports on
successful ZFN-targeted gene modification or correction by
homologous recombination in mammalian cell cultures
[15,24,25], it should be feasible to archive targeted knock-in
technologies that have thus been far inaccessible without rat ES
cells. Finally, since ZFN technology does not rely on using species-
specific embryonic stem cell lines, it should be possible to adapt it
to other mammalian species such as pigs, cattle, and monkeys,
where it is possible to harvest and manipulate fertilized embryos.
The X-SCID rats established in this study provide not only a
valuable in vivo model for evaluating drug treatment or gene
therapy approaches, but also a system for assaying novel
anticarcinogenic effects on transplanted malignancies. There is a
growing need for animal models with which to carry out in vivo
studies using human cells, tissues or organs as chimeras such as
humanized models [26,27,28]. X-SCID and SCID mice homo-
zygous for Il2rg- and Prkdc- alleles with a non-obese diabetic
background are a powerful tool for the xenotransplantation of
human tissues or potentially human ES/iPS cells. This could lead
to advances in our understanding of human hematopoiesis,
immunology, cancer biology, infectious diseases, and regenerative
medicine [29,30,31]. Humanized rats, if generated by ZFN
technology, could be powerful tools for pre-clinical testing during
drug development and be better models in various fields of
translational research.
Materials and Methods
Animals
All animal care and experiments conformed to the Guidelines
for Animal Experiments of Kyoto University, and were approved
by the Animal Research Committee of Kyoto University. F344-
Il2rgt
tm1Kyo X-SCID rats are deposited at the National Bio
Resource Project for the Rat in Japan (www.anim.med.kyoto-u.
ac.jp/nbr).
ZFN constructs
Custom-designed ZFNs plasmids for the rat Il2rg gene were
obtained from Sigma-Aldrich. The design, cloning, and validation
of the ZFNs was performed by Sigma-Aldrich [32]. ZFN design
involved using an archive of pre-validated two-finger and one-
finger modules [32,33]. The target region was scanned for
positions where modules exist in the archive. This allowed the
fusion of two or three such molecules to generate a five-finger
Figure 2 Abnormal lymphoid development in X-SCID rats. (a) Photograph of five week-old male X-SCID (Il2rg
2/Y) and F344 (+/Y) rats. (b)
Thymus of X-SCID and F344 rats. (c) Spleen of X-SCID and F344 rats. (d, e) Histological analysis of the thymus of X-SCID (X40) and F344 (X40) rats. The
thymus of the X-SCID rat was severely hypoplastic and consisted of an epithelial cell sheet. (f, g) Histological analysis of the spleen of X-SCID (X100)
and F344 (X100) rats. In the X-SCID spleen, the white pulp was virtually devoid of lymphocytes and the red pulp was occupied by a variety of myeloid
elements. (h) Dot plots representing CD3, CD45RA and CD161a for differentiation of T-, B- and NK cell sub-populations, and CD3, CD4 and CD8 for
demarcation of T-cell sub-populations in peripheral blood lymphocyte cells. The numbers shown in the quadrants are mean percentages. The circled
areas indicate cell populations that are referred to in the text.
doi:10.1371/journal.pone.0008870.g002
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fusion of two to three different modules that recognize a 15 bp site
on the bottom strand that lies 5–6 bp away. Measurements of
ZFNs for gene disruption activity were performed using the
Surveyor endonuclease (CEL-1) assay as described elsewhere [34].
Final candidate ZFNs were designed to recognize a site within the
boundary between exon 2 and intron 2 of the Il2rg gene as shown
in Figure S4.
Microinjection of ZFN mRNA
To prepare ZFN mRNA, ZFN-encoding expression plasmids
were linearized with XhoI and extracted with phenol-chloroform
by the standard method. Messenger RNA was transcribed in
vitro using a MessageMax
TM T7 mRNA transcription kit
(Epicentre) and polyadenylated using a A-Plus
TM Poly(A)
polymerase tailing kit (Epicentre). The resulting mRNA was
purified using a MEGAClear
TM kit (Epicentre) and finally
resuspended in RNase-free water at 10 ng/mlf o re a c hZ F N .
Approximately 2–3 pL of capped mRNA were injected into the
male pronuclei of zygotes by the same method that was used to
microinject DNA. Pronuclear stage embryos were collected
from F344/Stm and TM/Kyo females six weeks of age that had
been super-ovulated by injecting them with eCG (Serotropin,
Asuka Pharmaceutical Co.) and hCG (Gonatropin, Asuka
Pharmaceutical Co.). They were mated with males of the same
respective strain. The mRNA solution was injected and embryos
were cultured in KRB at 37.5uCw i t h5 %C O 2 and 95%
humidified air to promote their recovery. The embryos that
survived were transferred to the oviduct of pseudopregnant
females (Crlj:WI, 8–12wks).
Analysis of genome editing at ZFN target sites
Genomic DNA was extracted from the tail, brain, heart, and
liver using a GENEXTRACTOR TA-100 automatic DNA
purification system (Takara). PCR for each was carried out in a
total volume of 15 ml under the following conditions for 35 cycles:
94uC for 3 min for 1 cycle, 94uC for 30 sec, 60uC for 30 sec, and
72uC for 1 min. The final reaction mixture for each contained
100 ng of genomic DNA, 200 mM of each dNTP, 1.0 mM MgCl2,
0.66 mM of each primer, and 0.4 U of Taq DNA polymerase
(GibcoBRL).
For editing the ZFN cleavage site in the genome at the Il2rg
locus, three primer sets were designed to amplify small 292-bp,
middle 1509-bp, and large 3158-bp fragments as shown in Figure
S4. The PCR products were directly sequenced using the BigDye
terminator v3.1 cycle sequencing mix and the standard protocol
for an Applied Biosystems 3130 DNA Sequencer. The products
were also subcloned into the pCR4-TOPO vector (Invitrogen),
and plasmid DNA was prepared and sequenced on a 3130 DNA
Sequencer. All new sequence data is deposited in GenBank
(GU294902-GU294925).
Off-target site analysis
Off-target sites with the highest degree of similarity were
identified by searching the rat genome (RGSCv3.4) for matches
with the consensus sequence of each ZFP with appropriate spacing
of 5–6 bp. A list of these target sites is provided in Supplementary
Table 1. PCR primers were designed to flank the off-target sites as
detailed in Table S6. Reactions were performed for the founder
animals and the PCR products were directly sequenced on the
3130 DNA Sequencer.
RT-PCR and Western blotting
Total RNA was extracted using Isogen reagent (Nippon Gene)
from the spleen of five week-old rats. First strand cDNA was
synthesized from 5 mg of total RNA that had been treated using
DNase by using the oligo(dT)12–18 primer and SuperscriptII
reverse transcriptase (Invitrogen). PCR was performed with the
primers for Il2rg described in Figure S4 and with the Gapdh 59-
GGCACAGTCAAGGCTGAGAATG-39 and 59-ATGGTGGT-
GAAGACGCCAGTA-39. Western blotting was carried out using
the cell lysates from the spleens of five week-old rats by the
standard method. Signals were detected with antibodies against rat
IL2RG (M-20, Santa Cruz Biotechnology) and b-actin (AC-40,
Sigma Aldrich).
Immunofluorescence and histological analyses
Complete necroscopy examinations were performed on five
week-old Il2rg-deficient and wild-type male and female rats.
Peripheral blood specimens were collected from the caudal vena
cava. Serum immunoglobulin (Ig) levels were measured by
enzyme-linked immunosorbent assay (ELISA) using Rat IgG,
IgA and IgM ELISA Quantitation kits (Bethyl Laboratories).
Blood parameters for a complete blood cell count, a WBC
differential, and a reticulocyte count were measured using ADVIA
2120 flow cytometry (Block Scientific). For histopathology, tissues
were fixed in Bouin’s fluid and embedded in paraffin. The
embedded tissues were then sectioned at 5–7 mm thickness at
room temperature and stained with hematoxylin and eosin to
permit evaluation by light microscopy.
Figure 3 Tumor development from the xenotransplantation of
human ovarian cancer cells. (a) Growth curve of tumor develop-
ment after subcutaneous injection of A2780 human ovarian cancer cells
in F344 and X-SCID rats. *P,0.01, **P,0.001, and ***P,0.0001,
indicated in comparison with control F344. (b) The tumors became
large and grew quickly about 11 days after injection in X-SCID rats but
not in F344 rats. (c) Histology of the xenotransplanted tumors that
formed in X-SCID rats (X400). No lymphocytic infiltration was detected
in the tumors.
doi:10.1371/journal.pone.0008870.g003
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bone marrow, the spleen and peripheral blood were carried out
using IOTest Anti-Rat CD3-FITC/CD45RA-PC7/CD161a-APC
(Beckman Coulter) to differentiate T-, B- and NKcell sub-
populations and IOTest Anti-Rat CD3-FITC/CD4-PC7/CD8-
APC (Beckman Coulter) to enumerate T-cell sub-populations.
Anti-CD45 monoclonal antibodies (Beckman Coulter) were used
for the intracellular staining of lymphocytes. Mouse IgM, IgG1
and IgG2a antibodies (Beckman Coulter) were used as isotype-
matched controls. The cell samples were treated with FcR-
blocking reagent (Miltenyi Biotec) for 10 minutes, stained with the
fluorochrome-conjugated antibodies for 30 minutes, and washed
three times with PBS/10% FCS. Stained cell samples were
analyzed with a four-color FACS flow cytometer (FACSCalibur,
Becton Dickinson) using CellQuest software (Becton Dickinson).
Tumor cell xenotransplantation
The human ovarian cancer cell line A2780 was purchased from
the European Collection of Cell Cultures (ECACC). Cells were
cultured in RPMI1640 medium (GIBCO) with 10% heat-
inactivated FBS (Hyclone). Subcutaneous injections of 2610
5
A2780 cells with Matrigel (Becton Dickinson) were performed on
five week-old female rats. Tumors were measured by length (a) and
width (b) in millimeters using calipers, and tumor volumes (V) were
calculated according to the relationship V=ab
2/2, where a was the
longer of the two measurements. Human-specific PCR primers
were designed to amplify major histocompatibility complex class II
DQ beta 2 (HLA-DQB2) at exon 4 as follows: 59-CCTAGG-
GTGGTCAGACTGGA-39 and 59-AAAATCCCCCAAAACA-
AAGG-39.
Supporting Information
Figure S1 PCR analysis of 13 mutant founders for the zinc-
finger nuclease (ZFN) target site. For the analysis of the ZFN target
site at the Il2rg locus, three primer sets were used to amplify small
(a, 292-bp), middle (b, 1509-bp), and large (c, 3158-bp) fragments
for PCR. See Figure S4 for further details. PCR fragments were
electrophoresed through a 1-4% agarose gel. M: DNA molecular
weight marker wX174-HaeIII digest.
Found at: doi:10.1371/journal.pone.0008870.s001 (9.19 MB
TIF)
Figure S2 PCR analysis of genomic DNA isolated from several
tissues. Three primer sets were used to amplify small (a, 292-bp),
middle (b, 1509-bp), and large (c, 3158-bp) fragments for PCR.
See Figure S4 for further details. Genomic DNA (T: tail, B: brain,
H: heart, L: liver) was used as a template for PCR in zinc-finger
nuclease-modified founders (numbers 28, 35, 40, and 53) and G1
rats. PCR fragments were electrophoresed through a 1–4%
agarose gel. M: DNA molecular weight marker wX174-HaeIII
digest or Lambda DNA-HindIII digest.
Found at: doi:10.1371/journal.pone.0008870.s002 (6.28 MB
TIF)
Figure S3 Flow cytometric analysis of bone marrow lymphocyte
cells (a) and spleen lymphocyte cells (b) from five-week-old F344
and X-SCID rats. Dot plots represent CD3, CD45RA, and
CD161a for discrimination of T-, B-, and NK cell subpopulations;
and CD3, CD4, and CD8 for demarcation of T cell subpopula-
tions. The numbers shown in quadrants are mean percentages.
Circled areas indicate cell populations referred to in the text.
Found at: doi:10.1371/journal.pone.0008870.s003 (6.66 MB
TIF)
Figure S4 Zinc-finger nuclease pairs designed against the Il2rg
locus and primer sequences used for PCR analysis for the Il2rg
gene. Each exon is underlined. The start codon is indicated by a
red box. The three primer sets (small, middle, and large) used for
the PCR analysis of Il2rg are shown by boxes. Primers used for the
RT-PCR are shown as cDNA.
Found at: doi:10.1371/journal.pone.0008870.s004 (3.32 MB
TIF)
Table S1 Potential zinc-finger nuclease off-target sites.
Found at: doi:10.1371/journal.pone.0008870.s005 (0.14 MB
DOC)
Table S2 Backcrossing of zinc-finger nuclease-modified found-
ers to F344/Stm rats.
Found at: doi:10.1371/journal.pone.0008870.s006 (0.16 MB
DOC)
Table S3 Intercrossing of zinc-finger nuclease-modified found-
ers between males and females.
Found at: doi:10.1371/journal.pone.0008870.s007 (0.08 MB
DOC)
Table S4 Peripheral blood profiles of Il2rg-deficient (X-SCID)
rats.
Found at: doi:10.1371/journal.pone.0008870.s008 (0.09 MB
DOC)
Table S5 Differential counts of the white blood cells of Il2rg-
deficient (X-SCID) rats.
Found at: doi:10.1371/journal.pone.0008870.s009 (0.07 MB
DOC)
Table S6 Primer sequences for zinc-finger nuclease off-target
analysis.
Found at: doi:10.1371/journal.pone.0008870.s010 (0.14 MB
DOC)
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